Is Tafasitamab already on the market at home and abroad? What is the approximate price?

2020 Year 7 Month, the United States FDA accelerated approval of tanxituzumab combined with lenalidomide (lenalidomide) for the treatment of relapsed patients who are not suitable for autologous stem cell transplantation/refractory diffuse large B Monjuvi (tafasitamab-cxix) for adult patients with R/R DLBCL. 2025 Year 6 In March, the U.S. FDA expanded its indications and approved combination with lenalidomide and rituximab (rituximab) for the treatment of relapsed / refractory follicular lymphoma (FL).

2021 In 8 month, the European Medicines Agency (EMA) also granted conditional marketing authorization for the same R/R DLBCL population; in addition, Hong Kong, Macau, and Taiwan have all approved the combination regimen. 2025 Year 5 Month, China’s National Medical Products Administration (NMPA) officially approved tanxituzumab combined with lenalidomide for adults who are not suitable for autologous stem cell transplantation R/R DLBCL Patients, and has been clinically used in early access projects in Boao and other places, marking its official entry into the Chinese market.

Currently in the United States and Europe, the specific retail price of Monjuvi/Minjuvi has not been disclosed, but its dosage is 12 mg/kg intravenously infused and applied in a combined regimen, and the cost is expected to be considerable. Although there is no clear price yet, according to the market trend of CD19 antibody drugs, the cost per cycle is expected to be tens of thousands of dollars. In addition, China has not yet disclosed specific pricing information, and future prices will depend on importer pricing and the results of medical insurance negotiations.

Tanxituzumab has been launched in China and has been used for infusion, but it has not yet been included in the national medical insurance list. Therefore, patients still need to purchase drugs at their own expense or through early access projects, and the cost burden is still high. With the advancement of widespread clinical application and medical insurance negotiations, the price is expected to gradually decrease, and more eligible R/R DLBCL patients will benefit from this. Prior to this, if patients consider using this program, they should actively communicate with medical institutions and medical insurance departments to understand possible cost support paths and affordability.

Reference materials:https://www.fda.gov/drugs/